Prospective Evaluation of Testosterone Fluctuations During a Transition of Therapy From Degarelix to Leuprolide in Patients on Androgen Deprivation Therapy-Reference-Cited by-同舟云学术

Prospective Evaluation of Testosterone Fluctuations During a Transition of Therapy From Degarelix to Leuprolide in Patients on Androgen Deprivation Therapy

Published:2014-03 Issue:3 Volume:83 Page:670-674
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Zuckerman Jack M.^ORCID,Eure Gregg,Malcolm John,Currie Lilian,Given Robert

Publisher

Elsevier BV

Subject

Urology

Reference15 articles.

1. Cancer statistics, 2012;Siegel;CA Cancer J Clin,2012

2. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline;Loblaw;J Clin Oncol,2007

3. Management of locally advanced prostate cancer: a European consensus;Boccon-Gibod;Int J Clin Pract,2003

4. Gonadotropin-releasing hormone and its analogues;Conn;N Engl J Med,1991

5. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues;Weckermann;Eur Urol,2004

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elucidation of the mechanism of suppressed steroidogenesis during androgen deprivation therapy of prostate cancer patients using a mouse model;Andrology;2016-05-27

2. Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis;BMJ Open;2015-11-13

3. Management of Metastatic Hormone-Sensitive Prostate Cancer;Current Urology Reports;2015-02-13

4. Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonist;Basic and Clinical Andrology;2015